Skip to main content
Caplight Logo









Axinesis

Axinesis

Private
WavreHealthcare & Life Scienceshttps://axinesis.com/en

Last Round

M&A

Mar 10, 2026

Total Funding Raised

$1.93M

Momentum

Top 25%

of companies Caplight tracks

Company Overview

Axinesis operates in Healthcare & Life Sciences and is based in Wavre. It has raised $1.93M.

Axinesis is a medical technology company that develops robotic devices for upper limb neurorehabilitation to assist patients with motor and cognitive disorders.

Sector

Healthcare & Life Sciences

Verticals

Medical Devices, Industrial Robotics

Business Model

B2B

Customer Profile

Hardware Sales

AI Layer

Non-AI

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Pricing history

Caplight clients see full MarketPrice™ history and secondary transactions.

Book a demo

For institutional investors. Book with your work email.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

Momentum history

Caplight clients track how buyer interest and sentiment change over time.

Book a demo

For institutional investors. Book with your work email.

Axinesis Comparables

Compare Axinesis with similar companies based on industry and business-model similarity.

Axinesis comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Tyromotion
84%
Bionik Laboratories Corp.
81%
DIH Medical
80%
Book a demo to see all comparables

For institutional investors. Book with your work email.

Axinesis Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
M&AMar 10, 2026
Book a demo to see all funding rounds

For institutional investors. Book with your work email.

Key People

Founding team and executive leadership

Julien Sapin

CEO

Executive Team

For institutional investors. Book with your work email.

Axinesis Investors

Notable investors and investment history

Market signals

Structured signals derived from secondary market and firmographic data.

  • Aug 21, 2026

    Monthly visitors grew 99% MoM, reaching 1.7K.

  • May 15, 2026

    Monthly visitors increased 61% MoM, reaching 2.6K.

Book a demo to see all signals

For institutional investors. Book with your work email.

Axinesis Filings

Explore SEC and related filing metadata, where available.

Axinesis filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Book a demo

For institutional investors. Book with your work email.

Frequently Asked Questions

Common questions about Axinesis's valuation, stock price, and market status.

Is Axinesis a public or private company?

Axinesis is a private company.

What is the current stock price of Axinesis?

Axinesis is a private company, so its shares have no public market price. Caplight tracks Axinesis's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.

How much is Axinesis worth (valuation)?

Valuation information for Axinesis is not publicly available.

Can I buy Axinesis stock?

Axinesis shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.

When was Axinesis's last funding round?

Axinesis's most recent funding round was M&A on March 10, 2026.

Who are the main investors in Axinesis?

Key investors in Axinesis include Walloon Region (Belgium).

Will Axinesis IPO soon?

No public IPO plans have been announced for Axinesis.

How can I track Axinesis secondary market activity?

Caplight tracks bids, offers, and trades in Axinesis's shares on secondary markets.

Firmographic Details

HeadquartersWavre
Employee Range6
Year Founded2015
Last FundingMar 10, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Book a demo

For institutional investors. Book with your work email.

See something wrong or outdated?